William Laferriere’s Post

🔬 Exciting news on Cancer Research Funding from our friends at Alliance for Childhood Cancer: Below are highlights from the recently released FY25 LHHS report accompanying the House Labor-HHS bill. STAR Act receives $50 million, a $20 million increase from FY24. CCDI funding is set at $75 million, a $25 million increase from FY24. NIH funding remains steady at $48.581 billion, matching FY24 levels. NCI receives $7.875 billion, an increase of $651.1 million from FY24. ARPA-H will be absorbed into a new "National Institute on Innovation and Advanced Research" at NIH, with funding reduced from $1.5 billion to $500 million. CW Bill Young Transplantation Program: $39 million (flat funding). National Cord Blood Inventory: $19.266 million (flat funding). These allocations support critical research and advancements in cancer treatment and healthcare innovation. Stay tuned for more updates as we continue to support these vital initiatives! #CancerResearch #STARAct #CCDI #NIH #HealthcareInnovation

Florida Cancer Specialists & Research Institute (FCS) is leveraging its extensive informatics capabilities to advance blood cancer treatments through real-world evidence. Their research is being showcased at the Society for Hematologic Oncology 2024, highlighting the institute's commitment to improving patient care and outcomes. FCS's Real-World Evidence team collaborates with internal and external partners to provide insights that enhance treatment decisions and clinical outcomes. Dr. Gustavo Fonseca, FCS medical oncologist and haematologist, emphasized the significance of their work, stating, "With our robust clinical and research expertise and informatics capabilities, FCS has much to contribute to our clinical understanding and practical clinical applications across the spectrum of blood cancers and diseases." FCS President and Managing Physician Lucio N. Gordan, MD highlighted the impact of their investments, saying, "FCS has made forward-thinking investments in the development of unique, proprietary datasets. These are now yielding significant insights that are directly informing clinical decisions and improving patient outcomes worldwide." This initiative underscores FCS's dedication to advancing cancer care through innovative research and data-driven approaches. https://lnkd.in/eRMup7cP Stay informed and ahead of the curve by following Practical Patient Care on LinkedIn for the latest industry news and insights! #PracticalPatientCare #BloodCancerResearch #RealWorldEvidence #OncologyInnovation

Call for Abstracts – Poster Session Deadline: Tuesday, March 26, 2024, at 11:59 pm (AST Time) The UPR Comprehensive Cancer Center invites you to submit your abstract for a poster presentation at the 2nd UPRCCC Annual Scientific Congress "Advances in Cancer Care, Research and Health Policy in Puerto Rico" to be held from April 25- 26, 2024. The purpose of this conference is to bring together leading scientists to discuss recent research, and to open opportunities for dialogue and collaboration among participants. We highly encourage the UPRCCC Scientific Community (students and Investigators) to submit abstracts of their Research as part of their professional development and contribution to the Cancer field. We will highlight emergent projects in Cancer Research across the entire spectrum (e.g., basic science, clinical research, translational research, population sciences, community engagement, health policy, Trials in Progress, and Case Reports). Deadline for Abstract Submission: March 26, 2024 Abstract submission form and guidelines: https://lnkd.in/ey4sjceB

Part 4 of the guides developed by our interns: How to Find Information About Clinical Trials If you are interested in learning more about #clinicaltrials, there are various resources available to help you access information. Websites like ClinicalTrials.gov provide a comprehensive database of ongoing trials. You can also consult with your healthcare provider, local research institutions, or patient advocacy groups for tailored guidance. Presented here is a guide to finding information about clinical trials created by our talented high school interns. This information and other clinical trial guides can be found on our website at: https://lnkd.in/d27RJeuh Check out GCAR’s patient advocacy partners for more information about clinical trials: Asian Fund for Cancer Research, Children's Tumor Foundation, Cholangiocarcinoma Foundation, Cure Brain Cancer Foundation, National Brain Tumor Society, National Foundation for Cancer Research (NFCR), Ovarian Cancer Research Alliance , Pancreatic Cancer Action Network

A fantastic milestone for our portfolio company Concr! They recently announced that they have recruited the first patients to VISION - an observational study aimed at transforming the treatment of early triple-negative breast cancer (TNBC). This amazing next step allows for Concr to evaluate their therapeutic response predictive algorithm which is used to define biomarkers of chemotherapy and immunotherapy response in early Triple Negative Breast Cancer (TNBC). Read below to find out more about Concr and the VISION study. #TechBio #Oncology #ClinicalTrials #AI #PrecisionMedicine

Together we can change the approach to pancreatic cancer!   The role of multidisciplinary collaboration and centralized care is crucial in improving pancreatic cancer patient outcomes. A multistakeholder approach involving the Lombardy Welfare Directorate, clinicians and a patient association, proposed a 𝐡𝐮𝐛-𝐚𝐧𝐝-𝐬𝐩𝐨𝐤𝐞 𝐦𝐨𝐝𝐞𝐥 and a 𝐦𝐮𝐥𝐭𝐢𝐝𝐢𝐬𝐜𝐢𝐩𝐥𝐢𝐧𝐚𝐫𝐲 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 to pancreatic cancer. This article outlines the process and criteria set forth for  𝐩𝐚𝐧𝐜𝐫𝐞𝐚𝐬 𝐮𝐧𝐢𝐭 𝐢𝐦𝐩𝐥𝐞𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧, aiming to provide a structured framework for enhancing pancreatic cancer care. The Lombardy model offers a structured framework for enhancing pancreatic cancer care, with potential applicability to other regions and countries seeking to improve their cancer care infrastructure. 👉https://lnkd.in/egXnPAH9 Thanks to Gianpaolo Balzano, Michele Reni, Maria Di Bartolomeo, Marta Scorsetti, Augusto Caraceni, Piero Rivizzigno, Alessandro Amorosi, Alessandro Scardoni, Mohammad Abu Hilal, Giovanni Ferrari, Roberto Labianca, Massimo Venturini, Claudio Doglioni, Luca Riva, Riccardo Caccialanza. Humanitas Research Hospital, Humanitas University  Regione Lombardia #research #publication #ScienceDirect

🚀 Exciting News! 🚀 We're thrilled to announce that first patients have been recruited to VISION - our observational study aimed at transforming the treatment of early triple-negative breast cancer (TNBC)! VISION will not only identify biomarkers of therapy response but also enhance the precision of therapeutic predictions for individual patients using Concr’s cutting-edge FarrSight®-Twin alongside standard diagnostic tests. 🤝 AI-VISION: A synergistic collaboration This multi-disciplinary initiative brings together the expertise of Concr, The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and Durham University. Funded by Innovate UK, AI-VISION leverages the power of multi-modal data and Concr’s proprietary Bayesian frameworks to uncover innovative treatment pathways for TNBC. 🌟 Why this matters TNBC is an aggressive cancer and an alarming 40% of women die within 5 years of their initial cancer diagnosis. More reliable biomarkers and novel approaches to treatment stratification offer hope to significantly improve survival. This study is also set to contribute to the body of evidence supporting the efficacy and safety of advanced computational methods in enabling precision medicine, ultimately aiming to improve patient outcomes. Read the full press release here: https://lnkd.in/eBgbTEtu And stay tuned for updates as we embark on this journey to transform TNBC care! #TechBio #Oncology #TNBC #BreastCancer #DigitalTwin #ClinicalTrials #AI #PrecisionMedicine #FromCosmologyToOncology

The U.S. National Cancer Institute (NCI) has launched a pioneering initiative aimed at enhancing clinical trial enrollment across the nation. Amidst a challenging staffing landscape, the NCI has introduced the Virtual Clinical Trials Office (VCTO) program, designed to integrate remote research staff who will facilitate patient screening, enrollment, and education for NCI-funded trials. This approach not only addresses current staffing shortages but also aims to broaden access to clinical trials, particularly in underserved and minority communities. Managed by the Frederick National Laboratory for Cancer Research, this pilot program will support six U.S. clinical trial centers, including NCI-designated cancer centers and members of the Community Oncology Research Program. Learn more about this initiative and its impact on advancing cancer research and patient care: https://lnkd.in/eY7FUa_B #ClinicalTrials #CancerResearch #RemoteWork #PatientCare

📢 Oracle Head & Neck Cancer UK Launches £55,000 Small Grants Programme 📢 We’re thrilled to announce the launch of our Small Grants Programme aimed at advancing research to improve outcomes for head and neck cancer patients. With a total funding pool of £55,000, we’ll be supporting 1-3 innovative research projects that have the potential to translate into clinical practice, benefit patients directly, or lay the groundwork for future large-scale studies. We’re encouraging interdisciplinary collaboration, welcoming proposals from allied health professionals and researchers working in the following areas: 🔬 Early detection and diagnosis 💡 Novel treatment approaches 🏥 Addressing health inequalities 🌟 Improving patient experience and quality of life Applications are open until 6 December 2024, with successful projects announced in February 2025. Rozlyn Redd, Director of Delivery and Impact, says: “We are excited to provide funding for innovative projects that will directly impact patient outcomes, driving real advancements in the treatment and care of head and neck cancer patients.” For more information and to apply, visit: 🔗 https://loom.ly/X_IUoDI Let’s continue pushing the boundaries of research and patient care! 💙 #ResearchFunding #HeadAndNeckCancer #Innovation #PatientCare #OracleHNC #HealthcareResearch

📢 Oracle Head & Neck Cancer UK Launches £55,000 Small Grants Programme 📢 We’re thrilled to announce the launch of our Small Grants Programme aimed at advancing research to improve outcomes for head and neck cancer patients. With a total funding pool of £55,000, we’ll be supporting 1-3 innovative research projects that have the potential to translate into clinical practice, benefit patients directly, or lay the groundwork for future large-scale studies. We’re encouraging interdisciplinary collaboration, welcoming proposals from allied health professionals and researchers working in the following areas: 🔬 Early detection and diagnosis 💡 Novel treatment approaches 🏥 Addressing health inequalities 🌟 Improving patient experience and quality of life Applications are open until 6 December 2024, with successful projects announced in February 2025. Rozlyn Redd, Director of Delivery and Impact, says: “We are excited to provide funding for innovative projects that will directly impact patient outcomes, driving real advancements in the treatment and care of head and neck cancer patients.” For more information and to apply, visit: 🔗 https://loom.ly/X_IUoDI Let’s continue pushing the boundaries of research and patient care! 💙 #ResearchFunding #HeadAndNeckCancer #Innovation #PatientCare #OracleHNC #HealthcareResearch